Tuberculosis
(TB) could be a chronic condition, and has become a worldwide disease burden.
Manufacturers of TB drugs are focused on developing drugs that may shorten the
duration of treatment, and help to beat challenges of drug-susceptible TB and
drug-resistant TB. The treatment of TB is split into two types, like first line
treatment, second line treatment, and drug resistant treatment.
Advanced
technologies and introduction of novel therapies are expected to enhance the
duration of treating TB, however, most TB cases with currently available
medicines can require up to six months of treatment. However, despite of
existing medicines and ongoing TB treatment drugs innovations, there's
continuous have to improve patients’ access to appropriate TB medicines
particularly within the areas of multidrug-resistant TB (MDR TB) and pediatric
TB.
Key Market Trends
Hospitals/Clinics
are Expected to Witness the Fastest Growth within the Coming Future
The WHO’s
strategy to stop TB includes engaging all relevant healthcare providers in Tuberculosis
Drugs Market,
while control through public-private mix approach remains an important
component of the strategy. The TB prevalence rate is more in countries, like
China, India, and Africa, hence, the governments of those respective countries
try to decrease the speed by increasing government initiatives and therefore
the number of hospitals.
As per 2019
Global Tuberculosis Report by the WHO, developing countries accounted for many
of the worldwide total TB cases, including India (27%), China (9%), Indonesia
(8%), and therefore the Philippines (6%). The developing countries mostly
depend upon the hospitals for healthcare access. Hence high incidence within
the regions will boost the market in hospitals and clinics.
Tuberculosis Drugs Market –
Restraints
The
increasing incidence of drug recall may be a major factor restraining the Tuberculosis
Drugs market growth. Manufacturers of TB drug
face challenges like increasing product recalls because of factors like packaging
or manufacturing flaws. for example, in 2018, Sandoz recalled its batch of
wrongly-packed tuberculosis (TB) drugs in India. Furthermore, in 2016, Novartis
manufactured a drug Onecure which was recalled by the Philippines Food and Drug
Administration for insufficient amount of rifampicin within the drug.
The high
pricing of medicine is another factor restraining the expansion of the market.
Second line treatment drugs are highly priced compared to first line treatment
with more side effects and high level toxicity.
Comments
Post a Comment